Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations

Journal of Thoracic Oncology

Volumn 9, Issue 8, 2014, Pages 1171-1179

  Chen, Yen Fu ^a   Hsieh, Min Shu ^b   Wu, Shang Gin ^a   Chang, Yih Leong ^b   Shih, Jin Yuan ^a   Liu, Yi Nan ^a   Tsai, Meng Feng ^c   Tsai, Tzu Hsiu ^a   Yu, Chong Jen ^a   Yang, James Chih Hsin ^a,b   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c DA YEH UNIVERSITY   (Taiwan)

Author keywords

EGFR mutation; EML4 ALK fusion; KRAS mutation; Lung adenocarcinoma; Reverse transcription polymerase chain reaction; ROS1 fusion

Indexed keywords

CRIZOTINIB; PEMETREXED; B LYMPHOCYTE ANTIGEN; EGFR PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; HLA ANTIGEN CLASS 2; INVARIANT CHAIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RAS PROTEIN; ROS1 PROTEIN, HUMAN; SDC4 PROTEIN, HUMAN; SLC34A2 PROTEIN, HUMAN; SODIUM PHOSPHATE COTRANSPORTER 2B; SYNDECAN 4;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CD74 ROS1 FUSION GENE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FUSION GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROS1 GENE; ADENOCARCINOMA; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROGNOSIS; SEX DIFFERENCE; SURVIVAL RATE; TAIWAN; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE-FREE SURVIVAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIB; SURVIVAL RATE; SYNDECAN-4; TAIWAN;

EID: 84905815103     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000232     Document Type: Article

References (38)

1. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
2. Blackhall F, Thatcher N, Booton R, Kerr K. The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer. Lung Cancer 2013;79:101-103.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
4. Rosell R, Carcereny E, Gervais R, et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
5. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
6. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
7. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923.
8. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520.
9. Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006;118:963-969.
10. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
11. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
12. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4- ALK. J Clin Oncol 2009;27:4247-4253.
13. Wong DW, Leung EL, So KK, et al.; University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-1733.
14. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17.
15. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
16. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30: 863-870.
17. Shaw AT, Camidge DR, Engelman JA. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012;30:482S (suppl; abstract 7508).
18. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18:4570-4579.
19. Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013;37:554-562.
20. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-381.
21. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012;18:4449-4457.
22. Cai W, Li X, Su C, et al. ROS1 fusions in Chinese patients with nonsmall- cell lung cancer. Ann Oncol 2013;24:1822-1827.
23. Go H, Kim DW, Kim D, et al. Clinicopathologic analysis of ROS1- rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol 2013;8:1445-1450.
24. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
25. Rosell R, Moran T, Queralt C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
26. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734.
27. Hunt JD, Strimas A, Martin JE, et al. Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. Cancer Epidemiol Biomarkers Prev 2002;11:1405-1412.
28. Travis WD, Muller-Hermelink HK, Harris CC. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
29. Rami-Porta R, Ball D, Crowley J, et al.; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593-602.
30. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
31. Cigarette smoking among adults-United States, 2006. MMWR Morbid Mortal Wkly Rep. 2007;56:1157-1161.
32. Tsai TH, Su KY, Wu SG, et al. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J 2012;39:677-684.
33. Tsai TH, Yang CY, Ho CC, et al. Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUSassisted bronchoscopy. Lung Cancer 2013;82:420-425.
34. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian neversmokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010;28:4616-4620.
35. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
36. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4- ALK-positive lung adenocarcinoma. J Clin Pathol 2010;63:1066-1070.
37. Lee HJ, Seol HS, Kim JY, et al. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann Surg Oncol 2013;20:200-208.
38. Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer 2014;83:168-173.